Validation of Plasma Proteomic Biomarkers Relating to Brain Amyloid Burden in the EMIF-Alzheimer’s Disease Multimodal Biomarker Discovery Cohort
暂无分享,去创建一个
J. Molinuevo | P. Scheltens | O. Blin | F. Barkhof | G. Frisoni | P. Visser | M. Tsolaki | S. Lovestone | K. Sleegers | S. Engelborghs | R. Vandenberghe | A. Morgan | P. Johannsen | F. Verhey | L. Frölich | J. Streffer | L. Bertram | R. Bordet | A. Lleó | J. Richardson | H. Zetterberg | A. Wallin | P. Kettunen | A. Nevado-Holgado | L. Rami | C. Teunissen | C. Legido-Quigley | A. Hye | S. Westwood | Liu Shi | B. Morgan | Y. Freund-Levi | M. Ten Kate | M. T. Kate | P. Martínez-Lage | N. Buckley | A. Baird | I. Bos | S. Vos | S. Gabel | J. Popp | V. Dobričić | Karen Meersmans | A. Kormilitzin | M. Tainta | Isabel Sala | E. D. De Roeck | N. Ashton | Sneha N Anand | S. Baker | E. D. Roeck | G. Peyratout | M. ten Kate | Abdul Hye | J. Richardson
[1] J. Cummings,et al. Repurposed agents in the Alzheimer’s disease drug development pipeline , 2020, Alzheimer's Research & Therapy.
[2] J. Cummings,et al. Alzheimer's disease drug development pipeline: 2019 , 2019, Alzheimer's & dementia.
[3] Magda Tsolaki,et al. Inflammatory biomarkers in Alzheimer's disease plasma , 2019, Alzheimer's & Dementia.
[4] W. M. van der Flier,et al. Plasma Protein Biomarkers for the Prediction of CSF Amyloid and Tau and [18F]-Flutemetamol PET Scan Result , 2018, Front. Aging Neurosci..
[5] R. Dobson,et al. The EMIF-AD Multimodal Biomarker Discovery study: design, methods and cohort characteristics , 2018, Alzheimer's Research & Therapy.
[6] J. Cummings,et al. Alzheimer's disease drug development pipeline: 2018 , 2018, Alzheimer's & dementia.
[7] C. Rowe,et al. High performance plasma amyloid-β biomarkers for Alzheimer’s disease , 2018, Nature.
[8] James G. Bollinger,et al. Amyloid β concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis , 2017, Alzheimer's & Dementia.
[9] A. von Gunten,et al. Interaction between personality traits and cerebrospinal fluid biomarkers of Alzheimer’s disease pathology modulates cognitive performance , 2017, Alzheimer's Research & Therapy.
[10] P. Martínez-Lage,et al. Beneficial effect of bilingualism on Alzheimer's disease CSF biomarkers and cognition , 2017, Neurobiology of Aging.
[11] P. Visser,et al. Relation of Odor Identification with Alzheimer's Disease Markers in Cerebrospinal Fluid and Cognition. , 2017, Journal of Alzheimer's disease : JAD.
[12] R. Sims,et al. The Correlation between Inflammatory Biomarkers and Polygenic Risk Score in Alzheimer's Disease. , 2017, Journal of Alzheimer's disease : JAD.
[13] R. Dobson,et al. Complement Biomarkers as Predictors of Disease Progression in Alzheimer's Disease. , 2016, Journal of Alzheimer's disease : JAD.
[14] J. Molinuevo,et al. Clinical and biomarker profiling of prodromal Alzheimer's disease in workpackage 5 of the Innovative Medicines Initiative PharmaCog project: a ‘European ADNI study’ , 2016, Journal of internal medicine.
[15] K. Blennow,et al. Alzheimer’s disease—subcortical vascular disease spectrum in a hospital-based setting: Overview of results from the Gothenburg MCI and dementia studies , 2016, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[16] H. Struyfs,et al. A DECADE OF CEREBROSPINAL FLUID BIOMARKERS FOR ALZHEIMER’S DISEASE IN BELGIUM , 2016, Alzheimer's & Dementia.
[17] C. T. Hehir,et al. Blood-Based Biomarker Candidates of Cerebral Amyloid Using PiB PET in Non-Demented Elderly. , 2016, Journal of Alzheimer's disease : JAD.
[18] R. Dobson,et al. Blood Protein Markers of Neocortical Amyloid-β Burden: A Candidate Study Using SOMAscan Technology , 2015, Journal of Alzheimer's disease : JAD.
[19] D. Y. Lee,et al. Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. , 2015, JAMA.
[20] A. Fagan,et al. Guidelines for the standardization of preanalytic variables for blood-based biomarker studies in Alzheimer's disease research , 2015, Alzheimer's & Dementia.
[21] Lennart Thurfjell,et al. Blood protein predictors of brain amyloid for enrichment in clinical trials? , 2015, Alzheimer's & dementia.
[22] P. Dupont,et al. Amyloid imaging in cognitively normal older adults: comparison between 18F-flutemetamol and 11C-Pittsburgh compound B , 2015, European Journal of Nuclear Medicine and Molecular Imaging.
[23] Magda Tsolaki,et al. Plasma proteins predict conversion to dementia from prodromal disease , 2014, Alzheimer's & Dementia.
[24] Magda Tsolaki,et al. Alzheimer's disease biomarker discovery using SOMAscan multiplexed protein technology , 2014, Alzheimer's & Dementia.
[25] Dina Aronzon,et al. tranSMART: An Open Source Knowledge Management and High Content Data Analytics Platform , 2014, AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science.
[26] Michael W. Weiner,et al. The future of blood-based biomarkers for Alzheimer's disease , 2014, Alzheimer's & Dementia.
[27] J. Clarimón,et al. Relationship between β-Secretase, inflammation and core cerebrospinal fluid biomarkers for Alzheimer's disease. , 2014, Journal of Alzheimer's disease : JAD.
[28] Frederik Barkhof,et al. Optimizing patient care and research: the Amsterdam Dementia Cohort. , 2014, Journal of Alzheimer's disease : JAD.
[29] Magda Tsolaki,et al. Plasma Based Markers of [11C] PiB-PET Brain Amyloid Burden , 2012, PloS one.
[30] Michelle K. Lupton,et al. Complement activation as a biomarker for Alzheimer's disease. , 2012, Immunobiology.
[31] M. Folstein,et al. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS—ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease , 2011, Neurology.
[32] Christian Humpel,et al. Identifying and validating biomarkers for Alzheimer's disease , 2011, Trends in biotechnology.
[33] Susan M Resnick,et al. Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease. , 2010, Archives of general psychiatry.
[34] Beatriz Bosch,et al. Increased Cortical Thickness and Caudate Volume Precede Atrophy in Psen1 Mutation Carriers , 2010, Alzheimer's & Dementia.
[35] B. Paul Morgan,et al. Implication of Complement System and its Regulators in Alzheimer’s Disease , 2009, Current neuropharmacology.
[36] Z. Khachaturian. Alzheimer's & Dementia: The Journal of the Alzheimer's Association , 2008, Alzheimer's & Dementia.
[37] Marcus D. Ruopp,et al. Youden Index and Optimal Cut‐Point Estimated from Observations Affected by a Lower Limit of Detection , 2008, Biometrical journal. Biometrische Zeitschrift.
[38] H. Soininen,et al. Development of Screening Guidelines and Clinical Criteria for Predementia Alzheimer’s Disease , 2008, Neuroepidemiology.
[39] G. Bernardi,et al. Cathepsin D expression is decreased in Alzheimer's disease fibroblasts , 2008, Neurobiology of Aging.
[40] Heather T. McFarlane,et al. Atomic structures of amyloid cross-β spines reveal varied steric zippers , 2007, Nature.
[41] Steven McGee,et al. Simplifying likelihood ratios , 2002, Journal of General Internal Medicine.
[42] S. Lovestone,et al. Proteome-based plasma biomarkers for Alzheimer's disease. , 2006, Brain : a journal of neurology.
[43] C. Jack,et al. Mild cognitive impairment – beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment , 2004, Journal of internal medicine.
[44] R. Petersen. Mild cognitive impairment as a diagnostic entity , 2004, Journal of internal medicine.
[45] T. Fujita,et al. The lectin‐complement pathway – its role in innate immunity and evolution , 2004, Immunological reviews.
[46] J. Trojanowski,et al. Expression profile of transcripts in Alzheimer's disease tangle‐bearing CA1 neurons , 2000, Annals of neurology.
[47] G. Lynch,et al. β-Amyloid increases cathepsin D levels in hippocampus , 1998, Neuroscience Letters.
[48] K. Jobst,et al. Mannan‐binding lectin in human serum, cerebrospinal fluid and brain tissue and its role in Alzheimer's disease , 1998, Neuroreport.
[49] R. Senior,et al. The serpin-enzyme complex (SEC) receptor mediates the neutrophil chemotactic effect of alpha-1 antitrypsin-elastase complexes and amyloid-beta peptide. , 1992, The Journal of clinical investigation.
[50] Robert Tibshirani,et al. Bootstrap confidence intervals and bootstrap approximations , 1987 .
[51] M. Folstein,et al. Clinical diagnosis of Alzheimer's disease , 1984, Neurology.